

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-----------------------|-------------------------|---|--------------------------|
| In re Application of: | Grillo-Lopez. |) | Examiner: Gary B. Nickol |
| | |) | |
| | |) | |
| Serial No: | 09/840,872 |) | Art Unit: 1642 |
| | |) | |
| Filed: | April 25, 2001 |) | |
| | |) | |
| Title: | INTRATHECAL |) | |
| | ADMINISTRATION OF |) | |
| | RITUXIMAB FOR TREATMENT |) | |
| | OF CENTRAL NERVOUS |) | |
| | SYSTEM LYMPHOMAS |) | |
| | |) | |

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Applicants request that the information on the attached Form PTO-1449 be considered by the Office during the pendency of the above-entitled application, pursuant to 37 C.F.R. 1.97. In accordance with 37 C.F.R. 1.97(h), the filing of the Information Disclosure Statement shall not constitute an admission that any information cited therein is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b). In the interest of full and complete disclosure to the Office, some or all of the art cited herein may not be considered by Applicant(s) or the Undersigned to be material under the standards of materiality defined in C.F.R. 1.56(b), enacted March 16, 1992, as amended September 8, 2000, and may merely be technical background which may be of interest to the Examiner.

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

The Commissioner is hereby authorized to charge any such fee, including any fee due with this submission, if the attached check(s) is in the wrong amount or otherwise improper or missing, in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account 03-3975, Order No. 037003-0280609.

Respectfully submitted,

Date: September 5, 2003



Suzanne L. Biggs
Registration No. 30,158 for
Direct Line: (858) 509-4095

Thomas A. Cawley, Jr.
Registration No. 40,944
PILLSBURY WINTHROP LLP
1600 Tysons Boulevard
McLean, VA 22102
Telephone: (703) 905-2000
Fax Line: (703) 905-2500

| | | |
|-------------------|----------------|---------------|
| Atty. Dkt. No. | M# | Client Ref. |
| | 037003-0280609 | 2000-30-0154A |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Grillo-Lopez

Appln. No.: 09/840,872

Filing Date: April 25, 2001

Date: September 5, 2003

Page

1

of

6

Examiner: Gary B. Nickol

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

| Examiner's Initials* | Document Number | Date MM/YYYY | Name (Family Name of First Inventor) | Class | Sub Class. | Filing Date (if appropriate) |
|-------------------------|--------------------|-----------------|---|-------|---------------|------------------------------------|
| | AR 4,348,376 | 09/1982 | Goldenberg | 424 | 1 | |
| | BR 4,454,106 | 06/1984 | Gansow, et al. | 424 | 1.1 | |
| | CR 4,460,559 | 07/1984 | Goldenberg | 424 | 1.1 | |
| | DR 4,472,509 | 09/1984 | Gansow, et al. | 436 | 548 | |
| | ER 4,665,077 | 05/1987 | Stringfellow, et al. | 514 | 269 | |
| | FR 4,816,567 | 03/1989 | Cabilly, et al. | 530 | 387 | |
| | GR 4,831,175 | 05/1989 | Gansow, et al. | 558 | 17 | |
| | HR 5,114,721 | 05/1992 | Cohen, et al. | 424 | 534 | |
| | IR 5,116,964 | 05/1992 | Capon, et al. | 536 | 27 | |
| | JR 5,182,107 | 01/1993 | Friden | 424 | 85.91 | |
| | KR 5,500,362 | 03/1996 | Robinson, et al. | 435 | 7.23 | |
| | LR 5,595,721 | 01/1997 | Kaminski, et al. | 424 | 1.49 | |
| | MR 5,674,492 | 10/1997 | Armitage, et al. | 424 | 144.1 | |
| | NR 5,677,180 | 10/1997 | Robinson, et al. | 435 | 328 | |
| | OR 5,693,780 | 12/1997 | Newman, et al. | 536 | 23.53 | |
| | PR 5,736,137 | 04/1998 | Anderson, et al. | 424 | 133.1 | |
| | QR 5,747,037 | 05/1998 | Noelle, et al. | 424 | 154.1 | |
| | RR 5,776,456 | 07/1998 | Anderson, et al. | 424 | 133.1 | |
| | SR 5,801,227 | 09/1998 | Fanslow, III et al. | 530 | 388.73 | |
| | TR 5,821,337 | 10/1998 | Carter, et al. | 530 | 387.3 | |
| | UR 5,833,987 | 11/1998 | Noelle, et al. | 424 | 154.1 | |
| | VR 5,843,398 | 12/1998 | Kaminski, et al. | 424 | 1.49 | |
| | WR 5,843,439 | 12/1998 | Anderson, et al. | 424 | 133.1 | |
| | XR 5,874,082 | 02/1999 | de Boer | 424 | 153.1 | |
| | YR 5,874,085 | 02/1999 | Mond, et al. | 424 | 195.11 | |
| | ZR 5,876,718 | 03/1999 | Noelle, et al. | 424 | 154.1 | |
| | AAR 5,716,614 | 02/1998 | Katz, et al. | 424 | 94.3 | |
| | BBR 6,001,358 | 12/1999 | Black, et al. | 424 | 154.1 | |

FOREIGN PATENT DOCUMENTS

| | Document Number | Date MM/YYYY | Country | Inventor Name | English Abstract | | Translation Readily Available | |
|--|--------------------|-----------------|---------|------------------|---------------------|----|-------------------------------------|----|
| | | | | | Enclosed | No | Enclose | No |
| | CCR 0 340 109 B1 | 05/1997 | EP | Steinman, et al. | | | | |
| | DDR 0 404,097 B1 | 09/1996 | EP | Bosslet, et al. | | | | |
| | EER 0 555 880 A2 | 08/1993 | EP | Aruffo, et al. | | | | |

| | | | | | | | | | |
|---|------|--|---------|----|-------------------|--|--|--|--|
| | FFR | 0 555 880 A3 | 08/1993 | EP | Aruffo, et al. | | | | |
| | GGR | WO 90/08187 | 07/1990 | WO | Reinherz, et al. | | | | |
| | HHR | WO 90/11294 | 10/1990 | WO | Howell, et al. | | | | |
| | IIR | WO 91/01133 | 02/1991 | WO | Goldstein, et al. | | | | |
| | JJR | WO 93/11161 | 06/1993 | WO | Whitlow, et al. | | | | |
| | KKR | WO 94/11026 | 05/1994 | WO | Anderson, et al. | | | | |
| | LLR | WO 95/06666 | 03/1995 | WO | Noelle, et al. | | | | |
| | MMR | WO 95/17202 | 06/1995 | WO | Armitage, et al. | | | | |
| OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) | | | | | | | | | |
| | NNR | Abrey <i>et al.</i> , Combination chemotherapy in primary central nervous system lymphoma," (abstract) <i>Proc. Am. Soc. Clin. Onc.</i> (1999) | | | | | | | |
| | OOR | Abrey <i>et al.</i> , Long-term survival in primary CNS lymphoma, <i>J. Clin. Oncol.</i> 16: 859-63 (1998) | | | | | | | |
| | PPR | Armitage <i>et al.</i> , Molecular and biological characterization of a murine ligand for CD40, <i>Nature</i> 357:80-82 (1992) | | | | | | | |
| | QQR | Behr <i>et al.</i> , Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies, <i>Clin. Cancer Res.</i> 5: 3304s-14s (1999) | | | | | | | |
| | RRR | Bejcek <i>et al.</i> , Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen, <i>Cancer Res.</i> 55: 2346-51 (1995) | | | | | | | |
| | SSR | Benoit <i>et al.</i> , Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin, <i>Immunopharmacology</i> 35: 129-139 (1996) | | | | | | | |
| | TTR | Berinstein <i>et al.</i> , Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, <i>Ann. Oncol.</i> 9: 995-1001 (1998) | | | | | | | |
| | UUR | Blay <i>et al.</i> , High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series, <i>J. Clin. Oncol.</i> 16: 864-871 (1998) | | | | | | | |
| | VVR | Bolognesi <i>et al.</i> , Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): <i>in vitro</i> and <i>in vivo</i> studies, <i>Br. J. Haematol.</i> 101: 179-88 (1998) | | | | | | | |
| | WWR | Capon <i>et al.</i> , Designing CD4 immunoadhesins for AIDS therapy, <i>Nature</i> 337: 525-531 (1989) | | | | | | | |
| | XXR | Chamberlain <i>et al.</i> , Primary central nervous system lymphoma: a role for adjuvant chemotherapy, <i>J. Neuro. Oncol.</i> 14: 271-275 (1992) | | | | | | | |
| | YYR | Cheng <i>et al.</i> , Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma, <i>Cancer</i> 82: 1946-51 (1998) | | | | | | | |
| | ZZR | Clodi <i>et al.</i> , Unbalanced expression of Fas and CD40 in mantle cell lymphoma, <i>Brit. J. Haematol.</i> 103: 217-9 (1998) | | | | | | | |
| | AAAR | Clynes <i>et al.</i> , Fc receptors are required in passive and active immunity to melanoma, <i>PNAS (USA)</i> 95:652-656 (1998) | | | | | | | |
| | BBBR | Coiffier <i>et al.</i> , Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study, <i>Blood</i> 92: 1927-1932 (1998) | | | | | | | |
| | CCCR | Czuczman <i>et al.</i> , Treatment of patients with low-grade B-cell lymphoma with the combinations of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, <i>J. Clin. Oncol.</i> 17: 268-76 (1999) | | | | | | | |
| | DDDR | DeAngelis <i>et al.</i> , "Primary Central Nervous System Lymphoma," IN <i>CANCER: PRINCIPLES & PRACTICE OF ONCOLOGY</i> 2233-2242 (DeVita <i>et al.</i> , eds. 1997). | | | | | | | |

| | | | | | |
|------|--|--|--|--|--|
| EEER | Deguchi <i>et al.</i> , Retention of biologic activity of human epidermal growth factor following conjugation of a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker, <u>Bioconjug. Chem.</u> 10: 32-37 (1999) | | | | |
| FFFR | Endo, <u>Gan To Kagaku Ryoho</u> 26: 744-748 (1999) | | | | |
| GGG | Fine <i>et al.</i> , Primary central nervous system lymphoma, <u>Annals Intern. Med.</u> 119: 1093-1104 (1993) | | | | |
| HHHR | Flavell <i>et al.</i> , Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone, <u>Int. J. Cancer</u> 62: 337-44 (1995) | | | | |
| IIIR | Freilich <i>et al.</i> , Chemotherapy without radiation therapy as initial. Treatment for primary CNS lymphoma in older patients, <u>Neurology</u> 46: 435-439 (1996) | | | | |
| JJJR | Funakoshi <i>et al.</i> , Inhibition of human B-cell lymphoma growth by CD40 stimulation, <u>Blood</u> 83: 2787-2794 (1994) | | | | |
| KKKR | Funakoshi <i>et al.</i> , Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas, <u>J. Immunother. Emphasis Tumor Immunol.</u> 19: 93-101 (1996) | | | | |
| LLLR | Ghetie <i>et al.</i> , Anti-CD19 antibodies inhibit the function of the P-gp pump in multigrug-resistant B lymphoma cells, <u>Clin. Cancer Res.</u> 5: 3920-7 (1999) | | | | |
| MMM | Green <i>et al.</i> , Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS, <u>Virology</u> 241: 260-268 (1998) | | | | |
| NNNR | Gruss <i>et al.</i> , CD40/CD40 ligand interactions in normal, reactive and malignant lymphohematopoietic tissues, <u>Leuk. Lymphoma</u> 24: 393-422 (1997) | | | | |
| OOO | Hekman <i>et al.</i> , Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody <u>Cancer Immunol. Immunother.</u> 32:364-372 (1991) | | | | |
| PPPR | Herrlinger <i>et al.</i> , Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin, <u>J. Neurooncol.</u> 40: 1-9 (1998) | | | | |
| QQQ | Hollenbaugh <i>et al.</i> , The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, <u>EMBO J.</u> 11:4313-4321 (1992) | | | | |
| RRRR | Hollinger <i>et al.</i> , "Diabodies": small bivalent and bispecific antibody fragments, <u>Proc. Nad. Acad. Sci. USA</u> , 90:6444.-6448 (1993). | | | | |
| SSSR | Huwyler <i>et al.</i> , Brain drug delivery of small molecules using immunoliposomes, <u>Proc. Nat'l Acad. Sci. USA</u> 93: 14164-14169 (1996) | | | | |
| TTTR | Illidge <i>et al.</i> , The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma, <u>Blood</u> 94: 233-43 (1999) | | | | |
| UUUR | Janeway, Immunotherapy by peptides, <u>Nature</u> , 341: 482 (1989) | | | | |
| VVVR | Johnson <i>et al.</i> , Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system, <u>Blood</u> 82: 1848-1857 (1993) | | | | |
| WWW | Kiesel <i>et al.</i> , Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytotoxicity, <u>Leukemia Research</u> 11, 12: 1119 (1987) | | | | |

| | | | | | |
|-------|---|--|--|--|--|
| XXXX | Kramer <i>et al.</i> , Tc-99m LL-2 Fab' monoclonal antibody imaging in acquired immune deficiency syndrome-related lymphoma, <u>Cancer</u> 80: 2469-2477 (1997) | | | | |
| YYYY | Kroll <i>et al.</i> , Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means, <u>Neurosurgery</u> 42: 1083-99 (1998) | | | | |
| ZZZR | Ledbetter <i>et al.</i> , Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency, <u>Circ. Shock</u> 44: 67-72 (1994) | | | | |
| AAAA | Lederman <i>et al.</i> , Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help), <u>J. Exp. Med.</u> 175: 1091-1101 (1992) | | | | |
| BBBB | Leget <i>et al.</i> , Use of rituximab, the new FDA-approved antibody, <u>Curr. Opin. Oncol.</u> 10: 548-551 (1998) | | | | |
| CCCC | Lesser <i>et al.</i> , The chemotherapy of adult primary brain tumor, <u>Cancer Treat. Rev.</u> 19: 261-281 (1993) | | | | |
| DDDD | Li <i>et al.</i> , Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy, <u>Cancer Immunol. Immunother.</u> 47: 121-30 (1998) | | | | |
| EEEE | Lieberman <i>et al.</i> , Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion, <u>J. Neurosurg.</u> 82: 1021-1029 (1995) | | | | |
| FFFF | Linsley <i>et al.</i> , Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation, <u>J. Exp. Med.</u> 1783: 721-730 (1991) | | | | |
| GGG | Maloney <i>et al.</i> , IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, <u>Blood</u> 90: 2188-2195 (1997) | | | | |
| HHHH | Mansfield <i>et al.</i> , Characterization of RFB4-pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies, <u>Bioconjug. Chem.</u> 7: 557-63 (1996) | | | | |
| IIIR | Mason <i>et al.</i> , ¹¹¹ Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distributin of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases, <u>Neurology</u> 50: 438-444 (1998) | | | | |
| JJJJR | McLaughlin <i>et al.</i> , Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program, <u>J. Clin. Oncol.</u> 16: 2825-2833 (1998) | | | | |
| KKKK | McLaughlin <i>et al.</i> , Clinical status and opitimal use of rituximab for B-cell lymphomas, <u>Oncology (Huntingt)</u> 12: 1763-1777 (1998) | | | | |
| LLLL | Monjour <i>et al.</i> , Lymphomes malins non Hodgkiniens primitifs du système nerveux central, <u>Rev. Neurol. (Paris)</u> 148: 589-600 (1992) | | | | |
| MMM | Morrison <i>et al.</i> , Genetically engineered antibody molecules, <u>Adv. Immunol.</u> 44: 65-92 (1988) | | | | |
| NNNN | Morrison <i>et al.</i> , Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, <u>Proc. Natl. Acad. Sci. USA</u> , 81:6851-6855 (1984) | | | | |
| OOO | Murphy <i>et al.</i> , Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes, <u>Blood</u> 86: 1946-1953 (1995) | | | | |
| PPPP | Nguyen <i>et al.</i> , IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients, <u>Eur. J. Haematol.</u> 62: 76-82 (1999) | | | | |

| | | | | | |
|--------|--|--|--|--|--|
| QQQ | Offner <i>et al.</i> , T Cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis, <i>Science</i> 251: 430-432 (1991) | | | | |
| RRRR | O'Neill <i>et al.</i> , Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy?, <i>Int'l J. Radiation Oncol. Biol. Phys.</i> 33: 663-673 (1995) | | | | |
| SSSS | Orlowski <i>et al.</i> , Hodgkin's disease with leptomeningeal involvement, <i>Cancer</i> 53: 1833-1835 (1984) | | | | |
| TTTT | Padlan, A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, <i>Molec. Immun.</i> 28: 489-498 (1991) | | | | |
| UUUU | Padlan, Anatomy of the antibody molecule, <i>Molec. Immun.</i> 31: 169-217 (1994) | | | | |
| VVVV | Partridge <i>et al.</i> , Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, <i>Pharm. Res.</i> 15: 576-82 (1998) | | | | |
| WWWW | Pastan <i>et al.</i> , Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model, <i>Proc. Nat'l Acad. Sci. USA</i> 92: 2765-2769 (1995) | | | | |
| XXXX | Perez-Jaffe <i>et al.</i> , Cerebral spinal fluid involvement by Hodgkin's disease diagnosed by CSF cytology and immunocytochemistry, <i>Diagn. Cytopathol.</i> 20:219-223 (1999) | | | | |
| YYYY | Piro <i>et al.</i> , Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma, <i>Ann. Oncol.</i> 10: 655-61 (1999) | | | | |
| ZZZZ | Press <i>et al.</i> , Monoclonal antibody 1F2 (Anti-CD20) serotherapy of human B cell lymphomas, <i>Blood</i> 69: 584-591 (1987) | | | | |
| AAAA | Ravetch and Kinet, Fc receptors, <i>Annu. Rev. Immunol</i> 9:457-92 (1991) | | | | |
| BBBB | Reni <i>et al.</i> , Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature, <i>Ann. Oncol.</i> 8: 227-234 (1997) | | | | |
| CCCC | Sandor <i>et al.</i> , Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma, <i>J. Clin. Oncol.</i> 16: 3000-3006 (1998) | | | | |
| DDDD | Schabet <i>et al.</i> , Diagnose und therapie der meningosis neoplastica, <i>Nervenarzt</i> 63: 317-27 (1992) | | | | |
| EEEE | Stamenkovic <i>et al.</i> , A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas, <i>EMBO J.</i> 8: 1403-1410 (1989) | | | | |
| FFFF | Stone <i>et al.</i> , A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma, <i>Blood</i> 88: 1188-97 (1996) | | | | |
| GGG | Strauchen <i>et al.</i> , Chemotherapy in the management of intraocular lymphoma, <i>Cancer</i> 63: 1918-21 (1989) | | | | |
| HHHH | Tutt <i>et al.</i> , Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors, <i>J. Immunol.</i> 161: 3176-3185 (1998) | | | | |
| IIIIIR | Valentine <i>et al.</i> , B3.9 Structure and function of the B-cell specific 35-37 kDa CD20 protein, In: <i>Leukocyte Typing III</i> (McMichael, Ed., p. 440, Oxford University Press (1987) | | | | |

| | | | | | |
|------|---|--|--|--|--|
| JJJJ | Valle <i>et al.</i> , Activation of human B lymphocytes through CD40 and interleukin 4, <u>Eur. J. Immunol.</u> 19: 1463-1467 (1989) | | | | |
| KKKK | Valluri <i>et al.</i> , Combination treatment of intraocular lymphoma, <u>Retina</u> 15: 125-9 (1995) | | | | |
| LLLL | van Besien <i>et al.</i> , Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma, <u>Blood</u> 91: 1178-1184 (1998) | | | | |
| MMMM | Verhoeyen <i>et al.</i> , Reshaping human antibodies: Grafting an antilysozyme activity, <u>Science</u> 239: 1534-1536 (1988) | | | | |
| NNNN | Vlasveld <i>et al.</i> , Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19, <u>Cancer Immunol. Immunother.</u> 40:37-47(1995) | | | | |
| OOOO | Wang <i>et al.</i> , Induction of bcl-x by CD40 engagement rescues slg-induced apoptosis in murine B cells, <u>J. Immunol.</u> 155: 3722-5 (1995) | | | | |
| PPPP | White <i>et al.</i> , Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma, <u>Pharm. Sci. Technol. Today</u> 2: 95-101 (1999) | | | | |
| QQQQ | Wu <i>et al.</i> , Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody, <u>Drug. Metabol. Dispos.</u> 26: 937-9 (1998) | | | | |
| RRRR | Youle, Immunotoxins for central nervous system malignancy, <u>Semin. Cancer Biol.</u> 7: 65-70 (1996) | | | | |
| SSSS | | | | | |
| TTTT | | | | | |

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.